American Diabetes Association
2 files

Novel lipid species for detecting and predicting atrial fibrillation in patients with type 2 diabetes

posted on 2020-10-28, 21:52 authored by Ada AdminAda Admin, Yow Keat Tham, Kaushala S. Jayawardana, Zahir H. Alshehry, Corey Giles, Kevin Huynh, Adam Alexander T. Smith, Jenny Y. Y. Ooi, Sophia Zoungas, Graham S. Hillis, John Chalmers, Peter J. Meikle, Julie R. McMullen
The incidence of atrial fibrillation (AF) is higher in patients with diabetes. The goal of this study was to assess if the addition of plasma lipids to traditional risk factors could improve the ability to detect and predict future AF in patients with type 2 diabetes. Logistic regression models were used to identify lipids associated with AF/future AF from plasma lipids (n=316) measured from participants from the ADVANCE trial (n=3,772). To gain mechanistic insight, follow-up lipid analysis was undertaken in a mouse model which has an insulin-resistant heart and is susceptible to AF. Sphingolipids, cholesteryl esters and phospholipids were associated with AF prevalence, whereas two GM3 ganglioside species were associated with future AF. For AF detection and prediction, addition of 6 and 3 lipids, respectively, to a base model (12 conventional risk factors) increased the C-statistics (detection:0.661 to 0.725; prediction:0.674 to 0.715), and categorical net reclassification indices. GM3(d18:1/24:1) was lower in patients who developed AF, improved the C-statistic for the prediction of future AF, and was lower in the plasma of the mouse model susceptible to AF. This study demonstrates that plasma lipids have the potential to improve both the detection and prediction of AF in patients with diabetes.


This study was funded by National Health and Medical Research Council project grants to JRM (1045585, 1125514) and in part by the Victorian Government’s Operational Infrastructure Support Program. PJM and JRM are National Health and Research Council Senior Research Fellows (IDs 1042095, 1078985). The ADVANCE study was funded by the National Health and Medical Research Council of Australia (grants 211086 and 358395; trial registration: Unique identifier: NCT00145925). ZHA was supported by a scholarship from King Fahad Medical City (Saudi Arabia).


Usage metrics



    Ref. manager